Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

Oryzon Genomics (Spain) | Researchclopedia

Back to institutions

Oryzon Genomics (Spain)

Cornellà de Llobregatcompany

250

Works

17,762

Citations

66

h-index

Top Research Topics

HER2/EGFR in Cancer Research Breast Cancer Treatment Studies Advanced Breast Cancer Therapies

Top Researchers

Charles M. Perou University of North Carolina at Chapel Hill

2,024 works250,387 citationsh-index: 193

Recent Research

Quantitative HER2 tissue and plasma profiling predicts the activity of trastuzumab deruxtecan for breast cancer

Paolo Tarantino,Se-Eun Kim,et al.

20260 citations

Epigenetics and DNA Methylation

Histone Deacetylase Inhibitors Research

Acute Myeloid Leukemia Research

Cancer Treatment and Pharmacology

Monoclonal and Polyclonal Antibodies Research

Cancer Genomics and Diagnostics

Cancer Immunotherapy and Biomarkers

Retinal Development and Disorders

RNA Research and Splicing

Peter J. Park Broad Institute

808 works149,249 citationsh-index: 145

Joel S. Parker University of North Carolina at Chapel Hill

1,025 works123,651 citationsh-index: 135

Xavier Estivill

867 works90,845 citationsh-index: 128

Jordi Salas‐Salvadó Instituto de Salud Carlos III

1,100 works67,491 citationsh-index: 128

Isidró Ferrer Universitat de Lleida

1,169 works58,890 citationsh-index: 119

Abstract PS3-10-24: Biologic and Pathologic Correlations of the HER2DX Genomic Test in HER2+ Disease

E. Sanfeliu,Anabel Martínez-Romero,et al.

20260 citations

Abstract PS4-07-06: Independent validation of TNBCDX, a 15-gene genomic risk stratification tool for early-stage triple-negative breast cancer

F. Brasó-Maristany,E. Ciruelos,et al.

20260 citations

Abstract PS5-01-23: Validation of the HER2DX Genomic Test in First-Line Advanced HER2-Positive Breast Cancer: Identifying Long-Term Responders to THP

Marcin Kubeczko,Sandra Cobo,et al.

20260 citations

Abstract PS4-01-07: Prospective Validation of HER2DX in Early HER2+ Breast Cancer: Operational Feasibility of Centralized Genomic Screening in the DEFINITIVE Trial. Real-Time Insights from the First 80 Screened Patients

M. Gonzalez Rodriguez,K. Amilliano,et al.

20260 citations

Abstract GS1-04: Tumor infiltrating lymphocytes (TILs) and pathologic complete response (pCR) in stage II/III HER2+ breast cancer treated with taxane, trastuzumab, and pertuzumab (THP): secondary results from the ECOG-ACRIN EA1181/CompassHER2 pCR trial

S. S. Badve,F. Zhao,et al.

20260 citations